Статья
РЕСТЕНОЗ И ТРОМБОЗ ВНУТРИ СТЕНТА: ПАТОГЕНЕТИЧЕСКИЕ МЕХАНИЗМЫ РАЗВИТИЯ И ПРОГНОСТИЧЕСКИЕ МАРКЕРЫ
В статье рассматриваются различные аспекты развития осложнений после чрескожного коронарного вмешательства – рестеноза и тромбоза внутри стента. Необходимость такой комплексной оценки существующей проблемы продиктована тем, что, несмотря на все усилия, включающие расширение как технических, так и терапевтических возможностей, она остаётся далёкой от окончательного решения.
1. van der Hoeven B. L., Schalij M. J., van der Wall EE. Percutaneous coronary intervention with stent placement versus bypass operation in symptomatic multiple-vessel disease; lessons from an observational study. Ned Tijdschr Geneeskd 2005; Dec 17; 149 (51):2837–40.
2. Urban P., Gershlick A. H., Guagliumi G. et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113:11:1434–41.
3. Roy P., Torguson R., Okabe T. et al. Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsets. Catheter Cardiovasc. Interv. 2007; 70: 2: 167–72.
4. Lemos P. A., Saia F., Ligthart J. M. et al. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003; 108:3:257–60.
5. Svedman C., Ekqvist S., Moller H. et al. A correlation found between contact allergy to stent material and restenosis of the coronary arteries. Contact Dermatitis 2009; 60:158–64.
6. Farb A., Kolodgie F. D., Hwang J. Y. et al. Extracellular matrixe changes in stented human coronary arteries. Circulation 2004; 110:940–7.
7. Leytin V., Mykhaylov S., Starkey A. F. et al. Intravenous immunoglobulin inhibits anti-GPIIb-induced platelet apoptosis in a murine model of ITP. Br J Haematol 2006; 133:78–82.
8. Shojaie M., Sotoodah A., Roozmeh S. et al. Annexin V and anti-Annexin V antibodies: two interesting aspects in acute myocardial infarction. Thromb. 2009; Jul 21;7:13.
9. Kotova Y. N., Kostanova E. A., Rosenfeld M. A. et al. Effect of inhibitors of cysteine proteases in platelet and plasma units of blood coagulation system. Biol. Membrany 2009; 26 (5):1–7. Russian (Котова Я. Н., Костанова Е. А., Розенфельд М. А. и др.. Влияние ингибиторов цистеиновых протеиназ на тромбоцитарное и плазменное звенья системы свертывания крови. Биол.мембраны 2009; 26 (5):1–7).
10. Shitikova A. S. Thrombocytopathies, congenital and acquired.; edited by L. P. Papayan, O. G. Golovina. SPb. IRC MMA 2008; p. 320. Russian (Шитикова А. С. Тромбоцитопатии, врожденные и приобретенные; под ред. Л. П. Папаян, О. Г. Головиной. СПб. ИИЦ ВМА 2008; c.320).
11. Titov V. N., Lyakishev A. A., Kozlov S. G. et al. Stromal progenitor cells and blood leukocytes after implantation of drug-eluting stents. Kardiologiia 2010; 1:36–41. Russian (Титов В. Н., Лякишев А. А., Козлов С. Г. и др. Стромальные клетки-предшественники и лейкоциты крови после имплантации стентов с лекарственным покрытием. Кардиология 2010; 1:36–41).
12. Gabbasov Z. A., Koslov S. G., Saburova O. S. et al. Stromal progenitor cells and blood leukocytes after implantation of drug-eluting stents. Kardiologiia 2010; 50 (1):36–41.
13. Aicher A., Heeschen C., Mildner-Rihm C. et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor calls. Nat.Med. 2003; 9 (11):1370–6.
14. Ganz P., Vita J. A. Testing endothelial vasomotor function: nitric oxide, a multipotenent molecule. Circulation 2003; 108 (17); 2049–53.
15. Siow R. C. M., Churchman A. T. Adventitial growth factor signalling and vascular remodeling: potential of perivascular gene transfer from the outside-in. Cardiovasc Res 2007; 75:659–68.
16. Pasquinelli G., Tazzari P. L., Vaselli C. et al. Thoracic aortas from multiorgan donors are suitable for obtaining resident angiogenic mesenchymal stromal cells. Stem Cells 2007 Jul; 25 (7):1627–34.
17. Kovacic J. C., Macdonald P., Feneley M. P. et al. Safety and efficacy of consecutive cycles of granulocyte-colony stimulating factor, and an intracoronary CD133+ cell infusion in patients with chronic refractory ischemic heart disease: the G-CSF in angina patients with IHD to stimulate neovascularization (GAIN I) trial.Am Heart J. 2008 Nov; 156 (5):954–63.
18. Mudau M., Genis A., Lochner A. et al. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Aft 2012 May; 23 (4):222–31. doi: 10.5830/CVJA-2011–068.
19. Bulanovа E. L., Drapkina O. M., Gatsolaeva D. S. Prognostic significance of nitric oxide in cardiac patients. Rosiyskie medicinskie vesti 2007; 3:44–51. Russian (Буланова Е. Л., Драпкина О. М., Гацолаева Д. С. Прогностическое значение оксида азота у кардиохирургических больных. Российские медицинские вести 2007; 3:44–51).
20. Ivashkin V. T., Drapkina O. M. The clinical significance of nitric oxide and heat shock proteins. М.: GEOTAR- Media 2011. p. 376. Russian (Ивашкин В. Т., Драпкина О. М. Клиническое значе-ние оксида азота и белков теплового шока. М.: ГЭОТАР-Медиа 2011. 376 с).
21. Kisucka J., Chauhan A. K., Zhao B. Q. et al. Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood 2009 Jun 4;113 (23):6015–22.
22. Hofma S. H., van der Giessen W. J., van Dalen B. M. et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006 Jan; 27 (2):166–70.
23. Martin K. A., Rzucidlo E. M., Merenick B. L. et al. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol. 2004 Mar; 286 (3): 507–17.
24. Kandzari D. E., Leon M. B., Popma J. J. et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006 Dec 19; 48 (12):2440–7.
25. Chesnokova N. P., Mikhailov A. V., Morrison V. V. et al. The Infectious Process. – Publ. Academia estestvoznania. М. 2006. p.484. Russian (Чеснокова Н. П., Михайлов А. В., Моррисон В. В. и др. Инфекционный процесс. Изд-во Академия естествознания. М.2006. 484 с).
26. Ni H., Yuen P. S., Papalia J. M. et al. Plasma fibronectin promotes thrombus growth and stability in injured arteriolesroc. Natl Acad Sci U S A 2003. 100: 5:2415–9
27. Nekrasova O. E., Minin A. A., Kulik A. V. et al. Fibronectin regulation mitochondria`s shape and intracellular distribution. Biologicheskie membrany 2005; 22:105–12. Russian (Некрасова О. Е., Минин А. А., Кулик А. В. и др. Регуляция фибронектином формы и внутриклеточного распределения митохондрий. Биологические мембраны 2005; 22:105–12).
28. Reheman A., Hong Yang., Zhu G. et al. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood 2009 Feb 19;113 (8):1809–17.
29. Shawn J., Nguyen T. B., Tatary-Jain H. et al. Leptin-enhanced neointintinal hyperplasia is reduced by mTOR and PI3K inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2008; 105 (48):19006–11.
30. Legrand V. Therapy insight: Diabetes and drug-eluting stents. Nat Clin Pract Cardiovasc Med. 2007; 4:143–50.
31. Okumura K., Imamura A., Murakami R. et al. Endothelial function and early atherosclerotic changes. Future Cardiol. 2005 Jul;1 (4):501–8.
32. Bonta P. I., Pols T. W., van Tiel C. M. et al. Nuclear receptor Nurr1 is expressed in and is associated with human restenosis and inhibits vascular lesion formation in mice involving inhibition of smooth muscle cell proliferation and inflammation. Circulation 2010 May 11; 121 (18):2023–32.
33. Vogiatzi K., Apostolakis S., Voudris V. et al. Interleukin 8 gene polymorphisms and susceptibility to restenosis after percutaneous coronary intervention. J Thromb Thrombolysis 2010 Jan; 29 (1):134–40.
34. Vogiatzi K., Voudris V., Apostolakis S. et al. Genetic diversity of RANTES gene promoter and susceptibility to coronary artery disease and restenosis after percutaneous coronary intervention. Thromb Res. 2009 May; 124 (1):84–9.
35. van Tiel C. M., Bonta P. I., Rittersma S. Z. et al. А single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity. Circulation 2009 Aug 25; 120 (8):669–76.
36. Tiroch K., Koch W., Mehilli J. et al. P27 and P53 gene polymorphisms and restenosis following coronary implantation of drug-eluting stents. Cardiology 2009; 112 (4):263–9.
37. Bavan L., Midwood K., Nanchahal J. MicroRNA epigenetics: a new avenue for wound healing research. BioDrugs. 2011 Feb 1;25 (1):27–41.
38. Qin S., Zhang C. MicroRNAs in vascular disease. J Cardiovasc Pharmacol. 2011 Jan; 57 (1):8–12.
39. Silvestri P., Di Russo C., Rigattieri S. et al. MicroRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets. Recent Pat Cardiovasc Drug Discov. 2009 Jun; 4 (2):109–18.
40. Kannan M., Mohan K. V., Kulkarni S. et al. Membrane array-based differential profiling of platelets during storage for 52 miRNAs associated with apoptosis. Transfusion. 2009 Jul; 49 (7):1443–50.
41. Kondkar A. A., Bray M. S., Leal S. M. et al. VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost. 2010 Feb; 8 (2):369–78.
42. Zhu W., Zhu D., Lu S. et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol. 2012 Mar; 29 (1):384–91.
43. Xiao J., Lin H., Luo X. et al. miR-605 joins p53 network to form a p53: miR-605: Mdm2 positive feedback loop in response to stress. EMBO J. 2011 Feb 2; 30 (3):524–32.
44. Wang S., Tang Y., Cui H. et al. Let-7/miR-98 regulate Fas and Fas-mediated apoptosis. Genes Immun. 2011 Mar; 12 (2):149–54.
45. O’Donoghue M., Wiviott S. D. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation 2006 Nov 28; 114 (22): e600–6.
46. Ben-Dor I., Kleiman N. S,. Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol. 2009 Jul 15; 104 (2):227–33.
47. Can M. M., Tanboğa I. H., Türkyılmaz E. et al. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: Comparision of the PFA-100, multiplate electrical impedance aggregometry and verify now assays. Thromb Res. 2010 Apr; 125 (4): e132–7.
48. O’Donoghue M., de Lemos J. A., Morrow D. A. et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006 Aug 8; 114 (6):550–7.
49. Khuseyinova N., Imhof A., Rothenbacher D. et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis. 2005 Sep; 182 (1):181–8.
50. Koenig W., Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther. 2009 Feb;23 (1):85–92.